anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a storage container for a dental adhesive which can smoothly perform with high reproducibility a stable dripping operation and a fine dripping work such as rigorous dripping of a dripping amount, and can also suppress expansion of the adhesive stored inside due to a temperature raise when using the dental adhesive.  &lt;P&gt;SOLUTION: The storage container 10 for a dental adhesive includes a cylindrical container 11 capable of storing a liquid such as an adhesive. A discharge port 12 communicated with the outside is provided on one end side of this container 11, and the other end side of the container 11 is closed by a bottom wall 14. A tail part 13 protruding from this bottom wall 14 toward the opposite side of the discharge port 12 is formed. When dripping the liquid, neighborhood of the discharge port 12 can be supported by the thumb and index finger like handling writing implements such as a pencil. Since the tail part 13 can be supported near the root of the index finger, the stability of the holding state of the storage container 10a and the dripping state are excellent. Accordingly, rigorous dripping of a prescribed amount can be quickly and smoothly performed, and furthermore heat conduction to the liquid stored inside and its temperature raise can be suppressed.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:To obtain a calcium hydrogenphosphate good in bondability, increased in oil absorption and specific surface area and capable of being conveniently used as an excipient by allowing phosphoric acid to react with an alkaline Ca compd. or allowing an alkali metal phosphate to react with a Ca compd. to obtain a columnar calcium hydrogenphosphate which is hydrothermally treated. CONSTITUTION:This calcium hydrogenphosphate has 20-60m&lt;2&gt;/g specific surface area, &gt;=5ml/g static bulk volume and &gt;=1.5ml/g oil absorption. The average diameter of the primary particles measured by the electron microscope is 0.1-5mum and that of the aggregated second particles is 2-10mum. The salt is scaly and expressed by CaHPO4.mH2O (where 0&lt;=m&lt;=0.5). The salt is obtained by the traction of phosphoric acid with an alkaline Ca compd. or the reaction of an alkali metal phosphate with a Ca compd. in the presence of a polyvalent org. acid such as citric acid capable of being coordinated in an aq. medium to obtain a columnar calcium hydrogenphosphate which is hydrothermally treated at &gt;=60 deg.C.
In general, the invention is directed to techniques for prioritized presentation of implantable medical device (IMD) events based on relative importance. Given a prioritization of events, the techniques permit presentation of events in an order or format that directs a clinician&#39;s attention to important events. In some embodiments, a clinician simultaneously views events obtained from multiple IMDs associated with multiple patients, e.g., via single user interface, and is aided by an order or format of presentation that reflects event prioritization. In some cases, an IMD event with a priority above a predetermined threshold triggers special actions. As one example, an event with a high relative importance may be presented using a conspicuous text format. As another example, an event with a priority above the threshold may trigger a notification to a clinician, or other persons.
PROBLEM TO BE SOLVED: To obtain the subject composition useful for the prevention and treatment of diabetes or hepatic carcinoma by compounding a biologically obtainable oil or fat which contains a high concentration of arachidonic acid. SOLUTION: This composition contains an arachidonic acid-containing oil or fat, or further contains a docosahexaenoic acid-containing oil or fat or an oyster extract, as essential component. The arachidonic acid-containing oil or fat is obtained from a culture product produced by culturing an arachidonic acid producible microorganism (e.g. an arachidonic acid-producible microorganism belonging to the genus Mortierella) using glucose and a yeast extract, preferably in the presence of soybean oil, and the content of the arachidonic acid is &gt;=2 wt.%, preferably 10-99 wt.%, based on the total of the oil or fat. Further, when docosahexaenoic acid is compounded, its compounding ratio is preferably 0.5-1.5 times the arachidonic acid by weight. A health food for the prevention and treatment of diabetes or hepatic carcinoma can be obtained by using the composition.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to field of medicine and pharmacy and deals with pharmaceutical device which contains biological materials such as vaccines, which can be stabilised in certain glass-like water-soluble materials. It was suggested to form these glass-like materials in form of powder, suspended on non-water liquid for injection to patient. Glass-like material is placed on porous membrane, separately from eluent. When it is necessary to introduce biological material, eluent can be passed through membrane, solving glass and ensuring transfer of substance together with liquid into patient&#39;s body. ^ EFFECT: elaboration of improved device for introduction and storage of pharmaceutical product. ^ 14 cl, 4 dwg
An insulating substrate (10) coated with a thin copper layer is drilled to form through holes (16) and etched to define a circuit pattern (15). A liquid photopolymer solder mask layer ( 1) having a smooth planar outer surface is applied over the circuit pattern and processed to expose land areas (14) surrounding the through holes (16), the walls (18) of the solder mask surrounding the lands (14) being substantially cylindrical and roughened. A thin copper layer (20) is then applied by electroless deposition overall the exposed surfaces and an insulating resist layer (13) is applied over the copper on the planar surface of the mask (11). A thick copper layer is electroplated onto the copper coating in the through hole (16) and the resist (13), together with the underlying copper layer (20), is mechanically removed. The land (14) then forms the bottom surface of an indentation having copper coated sidewalls. &lt;IMAGE&gt;
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cleansing cosmetic exhibiting transparent liquid state, free from the troubles of thickening and clouding even by the mixing of a large amount of water and resistant to the lowering of the cleansing power and the deterioration of the appearance and the feeling in use.  &lt;P&gt;SOLUTION: The transparent liquid cleansing cosmetic is a composition containing (A) a polyglycerol fatty acid ester having an IOB of 0.75-1.2, (B) a nonionic surfactant other than polyglycerol fatty acid esters and having an IOB of ≥1.1, (C) a liquid oil component and (D) ≤12 wt.% water. The composition does not cause clouding when 50 pts. wt. of water is added to 100 pts. wt. of the composition.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
An achievement database (DB1) stores achievement information pertaining to children&#39;s learning. An achievement information transmission unit (11) reads out the achievement information stored in the achievement database (DB1) and transmits the achievement information (INF1) that has been read out. A detection unit (12) detects, on the basis of the achievement information (INF1), a child who is suspected of having a learning disability, and transmits a detection result (D1). A determination unit (13) transmits a determination result (D2) that is a result of determination which is on the reasonableness of the suspicion of the learning disability of the child and which is made by an expert on the basis of the detection result (D1). An examination guidance transmission unit (14) transmits, in accordance with the determination result (D2), examination guidance (EX) for urging an examination regarding the suspicion of the learning disability of the child. An agent of the child receives the determination result (D2) and the examination guidance (EX) through the communication unit (16).
A system and method in accordance with the invention allow a user to select when messages relating to medication events are sent and to select the content parameters of those messages. In one aspect, a user selects certain event types, the occurrence of which will cause a message to be sent to the user. For example, the user may select a message type that pertains to the availability of a medication in an automated dispensing machine for that user&#39;s patient. In another aspect, the user may customize the contents of the message to include or exclude certain information. For example, the user may desire the message to indicate only the patient&#39;s name and not the patient&#39;s gender or age. In yet another aspect, the user may filter messages so that only certain messages are sent. For example, the user may select a filter that permits only messages pertaining to his or her patients to be sent. The system further comprise a user interface disposed on an automated dispensing machine that enables a user to configure the messaging system as he or she desires. A method in accordance with the invention comprises selecting medication event types about which a message will be sent to the user, the content of the message, and filters for messages.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for efficiently proliferating and activating NK cells, and also to provide a medicine and a therapeutic method based on the combined use of the NK cells and a monoclonal antibody for enhancing the effects of therapeutic agent of monoclonal antibody through ADCC.  &lt;P&gt;SOLUTION: It is possible to selectively propagate NK cells and to obtain a large quantity of the NK cells at a high proliferating rate by adding glucocorticoid and IL-18 to peripheral blood monocytes after the culture initiation. The NK cells thus obtained are excellent in cytotoxic activity and in cell preservation stability. In addition, their ADCC enhancement effect is high, because the rate of CD16-positive cells is high. Consequently, the NK cells enhance the therapeutic effect of the therapeutic agent of monoclonal antibody through ADCC.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The disclosed lubricating suppository is formulated to have properties advantageous for coital use, including extraordinary water washability. The ingredients and phase relationships of the suppository composition provide a high degree of compatibility with water and with naturally-occurring vaginal moisture. The suppository composition contains a glyceride lubricant and can be lubricious with or without the presence of moisture. The suppository, which is solid at room temperature but melts in a short time at body temperature, is made by dissolving, for example, 10-30 parts by weight of high-HLB (e.g. &gt;14) nonionic surfactant in 50-70 parts by weight of a molten, water-soluble polyoxyethylene glycol component and by dispersing or emulsifying 10-20 parts by weight of the glyceride (e.g. a triglyceride of C6-C18 aliphatic carboxylic acids) included in the composition. In use, the suppository can be inserted prior to coitus and permitted to melt to a liquid, which is lubricious even in the absence of moisture, but still has the aforementioned extraordinary water washability.
PURPOSE:An endermic absorption promote extremely increasing endermic absorption in external preparation, containing a specific carboxylic acid amide as an active ingredient. CONSTITUTION:An endermic absorption promote containing a carboxylic acid amide (e.g. 2-ethyloctanamide) shown by the formula (R1-R3 are H, 1-20C straight chain, branched chain alkyl and at least one of R1-R3 is &gt;=9C alkyl and when R1 is straight alkyl, R2 and R3 are not H at the same time). As administration method of drug, an external preparation having no side effects on gastriointestinal disorder is preferable, but when a base used for ordinary external preparation is used alone, sufficiently endermic absorption of medicinal components blended is hardly carried out. As a method controlling permeability of drug through a corneum and raising endermic absorption of drug, the carboxylic acid amide extremely raises the effects. The amount of the absorption promote added is 0.01-5wt% based on the total amount of external preparation when it is used as an absorption promotion auxiliary and &gt;=10wt% as a base.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide powder overcoming disadvantages in deteriorating transparency because of light diffusion of soft focus effects and unavoidably forming a lusterless impression and having the soft focus effects with transparency.  &lt;P&gt;SOLUTION: The spherical powder is obtained by treating the surface of spherical powder to be a substrate. At least two kinds having a higher refractive index than that of the spherical powder to be the substrate are used as a surface-treating agent and treatments are successively carried out so as to provide an order of increasing refractive index. Thereby, surface-treated spherical powder is prepared. The resultant powder is included in the cosmetic. Silica, alumina, calcium carbonate, magnesium carbonate, etc., can be exemplified as the spherical powder.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To obtain a promoter of hydrolase activities capable of becoming a promoter of blood coagulation, promoting activities of protease, especially thrombin, trypsin, etc., containing a cyclic organic compound. CONSTITUTION:A promoter of hydrolase activity containing a compound shown by the formula (R&lt;1&gt; is residue of cyclic compound). The hydrolase is an enzyme capable of hydrolyzing a bond between Arg and an arbitrary amino acid residue and/or a bond between Lys and an arbitrary amino acid residue. The promoter of hydrolase activities by itself has no promoting action on blood coagulation but combination of the promoter with an enzyme promotes coagulation of blood and coagulates blood in a short time. Since the promoter of hydrolase activities does not change a serum component, examination values of various kinds of tests using serum can be accurately and stably measured. When containers for blood examination having the promoter of blood coagulation are prepared, blood tests can be simply carried out.
&lt;P&gt;PROBLEM TO BE SOLVED: To make inquiries for respective observations and diagnoses clear if a plurality of observations and diagnoses are written in an image reading report by a plurality of image reading doctors.  &lt;P&gt;SOLUTION: An image reading doctor belonging to an image reading department 6 reads a medical image 16 and creates an image reading report 20 via an image reading report creating terminal 12. A CPU 30 of the image reading report creating terminal 12 creates the image reading report 20 and report-attached information 21 as well. Observation and diagnosis identification information for identifying the written observation and diagnosis, and writer identification information for identifying the writer such as the image reading doctor who wrote the observation and diagnosis, etc. are correlated and recorded in the report-attached information 21. A CPU 24 of a diagnosis/treatment department terminal 10 selectively extracts and displays the observation and diagnosis written by each image reading doctor based on the report-attached information 21 when the image reading report 20 is displayed on a monitor 26. Accordingly, a requested doctor can easily discriminate the image reading doctor who wrote the observation and diagnosis.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The invention provides a 6-tert-butyl-8-diphenylphosphinoxy-2&#39;-F-ara purine nucleoside, and a preparation method and applications thereof. According to the preparation method, 6-tert-butyl-8-diphenylphosphinoxy-2&#39;-F-ara purine nucleoside is discovered in synthesis and activity screening of a large amount of compounds, and 6-tert-butyl-8-diphenylphosphinoxy-2&#39;-F-ara purine nucleoside possesses excellent anti-HL-60 cell activity. The structure of 6-tert-butyl-8-diphenylphosphinoxy-2&#39;-F-ara purine nucleoside is represented by formula I; and the synthesis method of 6-tert-butyl-8-diphenylphosphinoxy-2&#39;-F-ara purine nucleoside is studied. The preparation method is capable of solving problems in conventional synthesis methods, such as metal catalytic coupling reaction and free radical reaction of 6-hydrogen purine nucleoside, that too many steps are needed, yield is low, and operation is complex. Transition-metal catalyst (such as palladium, nickel, and ruthenium) or raw materials difficult to acquire are used in metal catalytic coupling reaction and free radical reaction of 6-hydrogen purine nucleoside. The invention also provides the preparation method used for preparing 6-tert-butyl-8-diphenylphosphinoxy-2&#39;-F-ara purine nucleoside with high efficiency.
PURPOSE:To obtain a cosmetic composition, capable of effectively absorbing ultraviolet rays within a wide wavelength region and simultaneously maintaining the ultraviolet ray absorptivity for a long period and excellent in feeling of transparency without causing problems such as a dark and dull appearance of a face when applied to the skin. CONSTITUTION:The objective cosmetic composition comprises 0.02-20wt.% ultrafine particles of spherical ferric oxide (hematite) having 0.03-0.09mum particle diameter. The ultrafine particles have effects on nearly complete cutting off of ultraviolet rays and sure protection of the skin. Furthermore, since the transmission of visible rays is not inhibited, problems such as a dark and dull appearance of a face are not caused. In addition, the fine particles may be mixed with fine particles of a metallic oxide such as zinc oxide or titanium oxide for use. In this case, if the particle diameter is &lt;=0.1mum, the feeling of transparency is not impaired. Fine particles of metallic oxide having &gt;0.1mum particle diameter, however, may be further added to regulate the color tone.
&lt;P&gt;PROBLEM TO BE SOLVED: To achieve a biological information collecting system having a high operability which can automatically collect the patient&#39;s biological information.  &lt;P&gt;SOLUTION: This biological information collecting system is equipped with a communication section 132, a hard disk 134, and a storage section 133. In this case, the communication section 132 receives measurement data which is acquired by measuring the patient, and is held by a communication device 120 being allotted for each patient while correlating the measurement data with a communication device ID which identifies the communication device 120. The hard disk 134 holds a relationship information file representing the corresponding relationship between the communication device ID and a patient ID which identifies the patient. The storage section 133 stores the measurement data which has been received in the communication section 132 based on the relationship information file and the patient ID which is held by the hard disk 134 while correlating them.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
This invention relates to a standard component 99mTC elution generator useful for medical purposes and consisting of prefabricated component parts. The main generator column of the device may be used both as an irradiation container and an elution container, enabling the user to supply activated or nonactivated parts. The main generator column made from by neutrns little activable materials serves first as reactor irradiation ampoule and after having been activated in the reactor by neutrons and after a simple adjustment serves directly as the generator column. It is filled with water insoluable molybdates or polymolybdates (with the molybdenum content in the range 10-40%), easily releasing 99mTc generated by radioactive decay of the mother 99Mo formed in it by neutron activation. This column filling serves originally as target material for reactor irradiations and afterwards it is directly used as the generator elution matrix. Accordingly, all components of the generator can be produced in a &#34;ready-to-use&#34; form and supplied as inactive material. When nonactivated parts are used, activation is performed on-site by a local reactor. The use of nonactivated parts is advantageous because they are more easily and more safely manufactured and transported. The invention further provides for efficient generation of 99mTC radionuclides from medium neutron flux irradiation of molybdenum in a natural isotopic mixture.
PROBLEM TO BE SOLVED: To obtain a tablet containing tocopherol succinate and excellent in oral administration touch by treating the tocopherol succinate by a specific means. SOLUTION: This tablet contains tocopherol succinate. The tablet preferably contains the tocopherol succinate having particle diameters of &lt;=250 μm in an amount of &gt;=99%. The tablet is obtained by grinding the tocopherol succinate, mixing the ground product with a preparation auxiliary and subsequently tableting the mixture. The tocopherol succinate includes natural type tocopherol succinate and synthetic type tocopherol succinate. The tocopherol also includes α, β, γ, and δ types, and further contains d-isomer, 1-isomer and d1-isomer.
&lt;P&gt;PROBLEM TO BE SOLVED: To stably disperse a silicone emulsion or a pearl agent in a liquid detergent for a long period of time.  &lt;P&gt;SOLUTION: A detergent composition contains a surfactant, water, the silicone emulsion or the pearl agent, a specific copolymer A and/or a specific copolymer B. The copolymer A is an alkyl-modified carboxyl group-containing water-soluble copolymer obtained by polymerizing 100 pts.wt. (meth)acrylic acid, 0.5-5 pts.wt. alkyl (meth)acrylate having a 18-24C alkyl group and 0-0.1 pt.wt. compound having two or more ethylenic unsaturated groups. A neutralized viscous liquid having 1 wt.% copolymer A concentration has the viscosity in a specified range or less and ≥90% transmittance, and the neutralized viscous liquid containing a specific amount of sodium chloride has the maximum viscosity in a specific range and ≥90% transmittance. The copolymer B is another alkyl-modified carboxyl group-containing water-soluble copolymer obtained by polymerizing 100 pts.wt. (meth)acrylic acid, 5-10 pts.wt. lauryl (meth)acrylate and 0-0.1 pt.wt. compound having two or more ethylenic unsaturated groups. Another neutralized viscous liquid having 1 wt.% copolymer B concentration has the viscosity in a specified range or less and ≥95% transmittance, and the neutralized viscous liquid containing a specific amount of sodium chloride has the maximum viscosity in a specific range and ≥95% transmittance.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:The titled composition, containing amorphous nicardipine or a salt thereof, and having improved absorbability from the intestinal mucous membrane and a coronary and cerebral vasodilator action. CONSTITUTION:A composition containing amorphous nicardipine [chemical name: 2,6-dimethyl-4-(3&#39;-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methyl ester-5-beta-(N-benzyl-N-methylamino)ethyl ester] or a salt thereof. The amorphous nicardipine or a salt thereof is preferably obtained by pulverizing the nicardipine or a salt thereof in a ball mill or in a vibrating ball mill into a fine powder. The nicardipine is useful as a remedy for cerebrl blood disorder, hypertension and angina pectoris, but is slightly soluble in the second solution specified in the ninth edition of the Japanese Pharmacopoeia. The poor enteric solubility makes the realization of the lasting pharmacentical diffucult. The amorphous nicardipine improves the absorbability from the intestinal tract.